clinical trial · NCT04449874
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.·phase1·active not recruiting·n = 498
Non-Small Cell Lung CancerColorectal CancerAdvanced Solid TumorsGDC-6036AtezolizumabCetuximabBevacizumabErlotinibGDC-1971Inavolisib
brief summary
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
started
Jul 29, 2020
primary completion
Dec 31, 2027
completion
Dec 31, 2027
last updated
Jun 2, 2026
official title
A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol